Method for preparing nucleic acid membrane and drug injection device using nucleic acid membrane

Abstract

The method for manufacturing the nucleic acid film of one embodiment of the present application includes the following steps: a mixing step in which a nucleic acid is put into distilled water or deionized water in a powder form to form a mixed solution; a stirring step in which the mixed solution subjected to the mixing step is stirred; a mixed solution coating step in which the mixed solution is coated on a molding mold corresponding to the form of the nucleic acid film to be completed; and a drying step in which the mixed solution coated on the molding mold is dried to change the mixed solution coated on the molding mold into a nucleic acid film; a groove portion recessed in a thickness direction is formed on the molding mold; a protruding portion corresponding to the groove portion is formed on the nucleic acid film subjected to the drying step, and protrudes from one surface of the nucleic acid film toward the skin of a human body.

Description

TECHNICAL FIELD

[0001] The present invention relates to a preparation method of a nucleic acid membrane and a drug injection device using the same, and more particularly, to a preparation method of a nucleic acid membrane and a drug injection device using the same, which prevent skin problems and can improve skin permeability of a drug by applying the nucleic acid membrane in a transdermal delivery technique depending on diffusion of a drug through a skin. BACKGROUND

[0002] Generally, most drugs are administered orally. However, some drugs, especially protein and peptide drugs, cannot be effectively absorbed by this method due to severe decomposition in the gastrointestinal tract, weak absorption at the intestinal cell membrane, and / or first-pass elimination by the liver.

[0003] Another drug administration technique is non-oral injection using a standard syringe or catheter. Injection with a needle causes needle phobia, substantial pain, and local skin damage in many patients. Collection of body fluids such as blood for diagnostic purposes causes similar anxiety. In addition, injection with a needle is not ideal for the continuous delivery or continuous diagnosis of a drug.

[0004] Another drug delivery technique is transdermal delivery, which generally depends on diffusion of a drug through a skin. This method has not been widely used due to insufficient skin permeability of many drugs. The outermost layer of the skin, i.e., the stratum corneum, is the main barrier to transdermal drug penetration. Once the drug reaches the depth of the dermis (below the epidermis), the drug rapidly diffuses to deep tissue layers and other parts of the body through the blood circulation.

[0005] In attempts to improve the speed of delivery of protein drugs through the skin, chemical enhancers, iontophoresis, electroporation, ultrasound, and thermal elements are used to supplement drug delivery. However, these techniques are not suitable for the form of some drugs, and often cannot provide delivery at a therapeutic level. These techniques sometimes cause unwanted skin reactions, and it is not practical to control the delivery of a drug over several hours or days of drug delivery. SUMMARY

[0006] Technical Problem to be Solved

[0007] An object of one aspect of the present invention is to provide a preparation method of a nucleic acid membrane and a drug injection device using the same, which prevent skin problems and can improve skin permeability of a drug by applying the nucleic acid membrane in a transdermal delivery technique depending on diffusion of a drug through a skin.

[0008] Technical Solution

[0009] The method of producing a nucleic acid membrane of one embodiment of the present application includes the following steps: a mixing step in which a nucleic acid is put into distilled water or deionized water in a powder form to form a mixed solution; a stirring step in which the mixed solution subjected to the mixing step is stirred; a mixed solution coating step in which the mixed solution is coated on a molding mold corresponding to a form of a nucleic acid membrane to be produced; and a drying step in which the mixed solution coated on the molding mold is dried to change the mixed solution coated on the molding mold into the nucleic acid membrane; wherein a groove portion recessed in a thickness direction is formed on the molding mold, and a protrusion portion corresponding to the groove portion and protruding from one surface of the nucleic acid membrane toward a skin of a human body is formed on the nucleic acid membrane subjected to the drying step.

[0010] The method of producing the nucleic acid membrane can further include a slant deposition step in which a coating layer is formed on one side of the nucleic acid membrane after the drying step to expose an end portion of the protrusion portion.

[0011] The method of producing the nucleic acid membrane can further include a slant deposition step in which a coating layer is formed on the molding mold except for an end portion of the groove portion before the mixed solution coating step.

[0012] The method of producing the nucleic acid membrane can further include a slant deposition step in which a coating layer is formed on the other side of the nucleic acid membrane after the drying step to make a portion corresponding to the protrusion portion open.

[0013] The method of producing the nucleic acid membrane can further include the following steps: a finishing coating step in which a finishing liquid is coated to wrap the coating layer after the slant deposition step; and a finishing drying step in which the finishing liquid is dried to change the finishing liquid into a finishing layer.

[0014] The method of producing the nucleic acid membrane can further include at least one of the following steps: a membrane obtaining step in which the nucleic acid membrane is separated from the molding mold after the drying step; a mold preparation step in which the molding mold is processed in a manner corresponding to a form of the nucleic acid membrane to be produced before the mixed solution coating step; and a surface treatment step in which a surface of the molding mold is treated to be hydrophobic before the mixed solution coating step.

[0015] In the mixing step, 1 to 100 parts by weight of a medicine can be further put into the mixed solution in a liquid phase or a powder or capsule form.

[0016] The nucleic acid can be extracted from at least one of a fishery by-product formed by processing of a water product and an agricultural by-product formed by processing of a plant.

[0017] The drug injection device using the nucleic acid membrane according to an embodiment of the present application includes a nucleic acid membrane prepared according to the aforementioned preparation method to be in contact with the skin of a human body, a finishing film layered on the nucleic acid membrane, and a drug filled between the nucleic acid membrane and the finishing film.

[0018] The drug injection device using the nucleic acid membrane can further include a boundary film layered between the nucleic acid membrane and the finishing film, and a decomposition solution filled between the boundary film and the finishing film and composed of distilled water or deionized water, wherein a piercing needle is formed on the finishing film to protrude toward the boundary film to pierce the boundary film, and the drug is filled between the nucleic acid membrane and the boundary film.

[0019] The drug injection device using the nucleic acid membrane according to an embodiment of the present application includes a nucleic acid membrane prepared by further putting 1 to 100 parts by weight of a drug in a liquid phase or a powder or a capsule form into the mixed solution in the mixing step.

[0020] The drug injection device using the nucleic acid membrane can further include a boundary film layered on the nucleic acid membrane, a finishing film layered on the boundary film, a piercing needle formed on the finishing film to protrude toward the boundary film to pierce the boundary film, and a decomposition solution filled between the boundary film and the finishing film and composed of distilled water or deionized water.

[0021] On one side of the nucleic acid membrane, a microneedle can protrude toward the skin of a human body.

[0022] The other side of the nucleic acid membrane can be concave to form a buffer groove corresponding to the microneedle.

[0023] The drug injection device using the nucleic acid membrane can further include a coating layer on one side of the nucleic acid membrane to expose the tip of the microneedle.

[0024] The drug injection device using the nucleic acid membrane can further include a coating layer on the other side of the nucleic acid membrane, and a portion corresponding to the microneedle is open.

[0025] On one side of the nucleic acid membrane, a drug delivery portion can protrude toward the skin of a human body, and a drug injection hole can be formed through the drug delivery portion to discharge the drug.

[0026] The drug injection device using the nucleic acid membrane can further include a coating layer on one side of the nucleic acid membrane, exposing the tip of the drug delivery part.

[0027] The drug injection device using the nucleic acid membrane can further include a coating layer on the other side of the nucleic acid membrane, opening a portion corresponding to the drug injection hole.

[0028] The drug injection device using the nucleic acid membrane can further include a protective film on one side of the nucleic acid membrane and detachable on one side of the nucleic acid membrane to open and close the drug injection hole.

[0029] Inventive Effects

[0030] The preparation method of the nucleic acid membrane and the drug injection device using the nucleic acid membrane according to one embodiment of the present application can prevent skin problems and improve skin permeability of a drug by applying the nucleic acid membrane in a transdermal delivery technique that relies on diffusion of a drug through the skin.

[0031] In addition, a microneedle, a buffer groove, a drug delivery part in which a drug injection hole is formed, can be easily formed on the nucleic acid membrane, and a certain thickness of the nucleic acid membrane can be formed.

[0032] In addition, the shape of the nucleic acid membrane can be maintained for a long time.

[0033] In addition, foreign matter can be prevented from being mixed in the nucleic acid membrane, and the degree of decomposition of the nucleic acid membrane can be improved.

[0034] In addition, a decomposition solution can be stably supplied to the nucleic acid membrane, and the supply of the drug can be stabilized.

[0035] In addition, a pattern according to the input form of the drug can be formed, and the input amount of the drug can be adjusted according to the pattern.

[0036] In addition, leakage of the drug from the drug injection hole can be prevented, foreign matter can be prevented from being mixed in the drug, and the nucleic acid membrane can be protected. BRIEF DESCRIPTION OF DRAWINGS

[0037] Figure 1 A flowchart of the preparation method of the nucleic acid membrane of Embodiment 1 of the present application is illustrated.

[0038] Figure 2 A diagram of the process state of the preparation method of the nucleic acid membrane of Embodiment 1 of the present application is illustrated.

[0039] Figure 3 A cross-sectional view of a molding die used in the preparation method of the nucleic acid membrane of Embodiment 1 of the present application is illustrated.

[0040] Figure 4 A photograph of a microneedle provided to a nucleic acid membrane of Embodiment 1 of the present application.

[0041] Figure 5 A diagram for illustrating a process state in which a coating layer is formed on a nucleic acid membrane by forming a coating layer on a molding die in a method for producing a nucleic acid membrane of Embodiment 2 of the present application.

[0042] Figure 6 A flowchart for illustrating a method for producing a nucleic acid membrane of Embodiment 2 of the present application.

[0043] Figure 7 A diagram for illustrating a process state in which a coating layer is formed on a nucleic acid membrane by forming a coating layer on a molding die in a method for producing a nucleic acid membrane of Embodiment 2 of the present application.

[0044] Figure 8 A flowchart for illustrating a method for producing a nucleic acid membrane of Embodiment 3 of the present application.

[0045] Figure 9 A diagram for illustrating a process state in which a coating layer is incorporated in a nucleic acid membrane in a method for producing a nucleic acid membrane of Embodiment 3 of the present application.

[0046] Figure 10 A cross-sectional view of a drug injection device using a nucleic acid membrane of Embodiment 1 of the present application.

[0047] Figure 11 A cross-sectional view of a drug injection device using a nucleic acid membrane of Embodiment 2 of the present application.

[0048] Figure 12 A cross-sectional view of a drug injection device using a nucleic acid membrane of Embodiment 3 of the present application.

[0049] Figure 13 A cross-sectional view of a drug injection device using a nucleic acid membrane of Embodiment 4 of the present application. DETAILED DESCRIPTION

[0050] Hereinafter, embodiments of the present application will be explained in detail with reference to the accompanying drawings, so that those skilled in the art to which the present application pertains can easily practice the present application. The present application can be realized in various ways, and is not limited to the embodiments described herein.

[0051] For the purpose of clearly explaining the present application, portions irrelevant to the explanation are omitted in the accompanying drawings, and the same or similar constituent elements are given the same reference numerals throughout the entire specification.

[0052] Throughout this specification, when a part is described as being "connected" to another part, this includes not only "direct connection" but also "indirect connection" with other components intervening. Furthermore, when a part is described as "including" a certain component, unless otherwise stated, this indicates that the other component may also be included, not that the other component is excluded.

[0053] Throughout this specification, when a layer, film, region, plate, or other component is described as being "upper" or "above" another component, this includes not only the situation where the component is "directly above" the other component but also situations where there is another component intervening. Furthermore, "upper" or "above" means being above or below the component, and does not necessarily mean being above relative to the direction of gravity.

[0054] Next, the method for preparing a nucleic acid membrane according to the first embodiment of the present invention will be described. Figure 1 FIG1 is a flow chart illustrating a method for preparing a nucleic acid membrane according to a first embodiment of the present invention. Figure 2 1 is a diagram illustrating the process of the method for preparing a nucleic acid membrane according to the first embodiment of the present invention. Figure 3 1 is a cross-sectional view illustrating a molding die used in the method for producing a nucleic acid membrane according to the first embodiment of the present invention. Figure 4 This is a photograph illustrating the microneedles included in the nucleic acid membrane according to the first embodiment of the present invention. Figure 5 This figure shows the process of directly forming a coating layer on a nucleic acid film in the method for producing a nucleic acid film according to the first embodiment of the present invention.

[0055] in, Figure 3 (a) is a diagram showing a first mold 301 having a needle groove 311 formed in the molding mold 5, Figure 3 (b) is a diagram showing a second mold 302 in which a buffer forming groove 312 and a needle groove 311 are formed in the molding mold 5. Figure 3 (c) is a diagram showing a third mold 303 in which a delivery groove 313 and an injection protrusion 314 are formed in the molding die 5 .

[0056] also, Figure 5 The upper part is a diagram showing an oblique deposition process for forming a coating layer 15 on the completed nucleic acid film 10, Figure 5 The lower part of FIG. 1 is a diagram showing a state where the coating layer 15 is fixed on the completed nucleic acid membrane 10 .

[0057] refer to Figures 1 to 5 The method for preparing a nucleic acid membrane according to the first embodiment of the present invention is a method for preparing a nucleic acid membrane 10 using nucleic acid 1b in powder form.

[0058] The nucleic acid 1b is extracted from at least one of a water product processing by-product formed by processing of a water product and an agricultural product processing by-product formed by processing of a plant.

[0059] As one example, the water product processing by-product can be composed of a milt of a salmon, a skin of a salmon, a milt of a chum salmon, a crab shell, an ink of a squid, a mixture thereof, or the like.

[0060] As another example, the agricultural product processing by-product can be composed of a yeast of a grain or a seed such as a beer yeast, a rice yeast, a barley yeast, or the like, a mixture thereof, or the like.

[0061] The nucleic acid 1b can include a salmon nucleic acid extracted from a salmon in the water product processing by-product. If the nucleic acid 1b includes the salmon nucleic acid, due to a poly deoxy ribo nucleotide (PDRN) component contained in the salmon nucleic acid, it is possible to contribute to treatment of a wound and a scar, regeneration of skin without mixing a specific drug. In addition, after a drug injection device is removed from the skin of a human body, it is possible to contribute to rapid healing of a skin wound caused by a microneedle.

[0062] The method of manufacturing the nucleic acid film of the first embodiment of the present application includes a mixing step S1, a stirring step S2, a mixed solution coating step S3, and a drying step S4.

[0063] In the mixing step S1, the nucleic acid 1b is put into the water solution 1a in the mixing container 1 to form a mixed solution.

[0064] The mixing container 1 shows a form in which the width becomes narrower as it approaches the bottom, and thus it is possible to stably stir the water solution 1a and the nucleic acid 1b. At this time, the water solution 1a is composed of distilled water or deionized water, and the nucleic acid 1b is in a powder form.

[0065] Thus, 0.5 parts by weight to 5 parts by weight of the nucleic acid 1b is put into 100 parts by weight of the water solution (distilled water or deionized water) 1a to form a mixed solution. The amount of the nucleic acid 1b put in can be adjusted according to the thickness of the nucleic acid film 10 finally completed.

[0066] As one example, the amount of the nucleic acid 1b put in can be 0.5 parts by weight to 2 parts by weight. In addition, the amount of the nucleic acid 1b put in can be 1 part by weight to 3 parts by weight. Further, the amount of the nucleic acid 1b put in can be 0.5 parts by weight to 3 parts by weight. That is, the amount of the nucleic acid 1b put in can be changed in units of 0.5 parts by weight between 0.5 parts by weight and 5 parts by weight.

[0067] When the amount of the nucleic acid 1b deviates from the predetermined numerical range, a hole is generated in the finally completed nucleic acid membrane 10 or the membrane shape cannot be shown, or a crack is generated in the finally completed nucleic acid membrane 10. In addition, when the finally completed nucleic acid membrane 10 is used, the decomposition time is prolonged, which causes a problem of delaying the skin permeation of the drug.

[0068] However, when the amount of the nucleic acid 1b belongs to the predetermined numerical range, the finally completed nucleic acid membrane 10 shows a stable membrane shape, and it is possible to prevent a crack from being generated in the finally completed nucleic acid membrane 10, and it is possible to easily decompose the finally completed nucleic acid membrane 10 by the decomposition solution 50 described later within a predetermined time, and it is possible to improve the skin permeation rate of the drug.

[0069] The mixing container 1 can be washed with deionized water, isopropyl alcohol, acetone, and deionized water in the above order, and then the aqueous solution 1a and the nucleic acid 1b are mixed, whereby it is possible to prevent contamination of the aqueous solution 1a and the nucleic acid 1b.

[0070] In particular, in the mixing step S1, 1 to 100 parts by weight of the drug 40 can be further added to the mixed solution in a liquid phase or a powder or a capsule form. That is, the amount of the drug 40 can be changed in units of 0.5 parts by weight between 1 and 100 parts by weight. The amount of the drug 40 can be adjusted according to the amount of penetration into the human skin.

[0071] Thus, the nucleic acid 1b and the drug 40 are both mixed in the aqueous solution 1a, and the nucleic acid 1b and the drug 40 can be integrated in the finally completed nucleic acid membrane 10.

[0072] In the stirring step S2, the mixed solution subjected to the mixing step S1 is stirred. In the stirring step S2, the inlet of the mixing container 1 is sealed with a sealing material 4 such as parafilm, and the mixed solution is stirred in the stirring unit 2.

[0073] As one example, when the stirring unit 2 uses a magnetic stirrer, a magnet 3 washed with deionized water can be immersed in the mixing container 1. At this time, the magnet 3 can be sealed with the sealing material 4.

[0074] In the stirring step S2, the mixed solution is maintained in a conical shape by rotating in only one direction, so that the nucleic acid 1b is uniformly mixed in the mixed solution.

[0075] In the stirring step S2, the rotation speed is 600 rpm to 1000 rpm for 10 hours to 24 hours. As one example, in the stirring step S2, the rotation speed can be 700 rpm for 1 hour to 1.5 hours, and the rotation speed can be further 900 rpm for 9 hours to 10 hours.

[0076] Also, the mixed solution can be left in a space blocked from ultraviolet rays and sunlight for the remaining time in the stirring step S2, so as to stabilize the mixing state of the mixed solution.

[0077] In the mixed solution coating step S3, the mixed solution stirred in the stirring step S2 is coated on the molding mold 5. The molding mold 5 can exhibit a necessary shape corresponding to the form of the finally completed nucleic acid membrane 10.

[0078] The amount of the mixed solution coated on the molding mold 5 can be adjusted according to the size and thickness of the finally completed nucleic acid membrane 10.

[0079] In the mixed solution coating step S3, vacuum treatment can be performed for about 1 hour or so (55 minutes to 70 minutes) in a state in which the mixed solution is coated on the molding mold 5, thereby stabilizing the coating state of the mixed solution on the molding mold 5 and promoting drying of the mixed solution.

[0080] In the drying step S4, the mixed solution coated on the molding mold 5 is dried so as to transform the mixed solution coated on the molding mold 5 into the nucleic acid membrane 10. In the drying step S4, the molding mold 5 on which the mixed solution is coated is dried at a certain temperature for a certain time in the drying unit 7.

[0081] In the drying step S4, drying can be performed for 2 days to 4 days in the drying unit 7 maintained at 40 degrees Celsius to 60 degrees Celsius. As an example, in the drying step S4, drying can be performed for 3 days to 4 days in the drying unit 7 maintained at 45 degrees Celsius to 50 degrees Celsius. When the temperature in the drying step S4 is lower than the critical temperature, the time required for drying increases, and when the temperature in the drying step S4 is higher than the critical temperature, causes such as cracks and the like can occur in the completed nucleic acid membrane 10.

[0082] Therefore, when the temperature in the drying step S4 is within the above critical temperature range and drying is performed for a certain time, a stable nucleic acid membrane 10 can be completed.

[0083] In the drying step S4, bubbles can be removed from the mixed solution dried on the molding mold 5 by the pipetting unit 8.

[0084] The method of manufacturing the nucleic acid membrane of the first embodiment of the present application can further include at least one of a surface treatment step S5, a mold preparation step S6, a membrane acquisition step S7, and an inclined deposition step S8.

[0085] In the surface treatment step S5, the surface of the forming mold 5 is treated to be hydrophobic before the mixed solution coating step S3. In the surface treatment step S5, the surface of the forming mold 5 can be treated to be hydrophobic by a surface treatment unit 6 that generates oxygen plasma. In the surface treatment step S5, the forming mold 5 that has passed through the surface treatment unit 6 can be dried at room temperature for about one day.

[0086] After the surface treatment step S5 , the surface of the forming mold 5 is transformed from hydrophilic to hydrophobic, so that the mixed liquid is coated on the forming mold 5 with a uniform thickness.

[0087] Since the surface of the molding die 5 is hydrophobic, a virtual film can be formed between the mixed solution and the molding die 5 , allowing the completed nucleic acid film 10 to be safely separated from the molding die 5 .

[0088] In the mold preparation step S6 , before the mixed solution coating step S3 , more specifically, before the surface treatment step S5 , the mold 5 is processed in a manner corresponding to the shape of the nucleic acid membrane 10 to be completed.

[0089] As an example, in the mold preparation step S6 , a molding mold 5 having a flat surface may be processed.

[0090] As another example, in the mold preparation step S6, the needle groove 311 may be formed by recessing the molding die 5. Thus, the molding die 5 may be composed of the first mold 301. Figure 3 As shown in (a), the surface of the first mold 301 can be recessed to form a needle groove 311 whose width becomes narrower along the thickness direction. As a result, the microneedles 11 are protruded from the nucleic acid film 10 that is finally completed.

[0091] As another example, in the mold preparation step S6, a buffer forming groove 312 may be formed on the molding mold 5. Thus, the molding mold 5 may be composed of the second mold 302. Figure 3 As shown in (b), the surface of the second mold 302 can be recessed to form a buffer groove 312 for accommodating the drug 40 described later. Furthermore, the buffer groove 312 can be further recessed to form a needle groove 311. Thus, the buffer groove 12 is formed on the final nucleic acid film 10, protruding toward the human skin. Furthermore, the microneedles 11 are formed on the outer surface of the buffer groove 12, protruding toward the human skin.

[0092] As another example, in the mold preparation step S6, the delivery groove 313 may be formed concavely on the molding mold 5, and on the other hand, the injection protrusion 314 may be formed protrudingly on the delivery groove 313. Thus, the molding mold 5 may be composed of the third mold 303. Figure 3As shown in (c), the surface of the third mold 303 can be recessed to form a delivery groove 313 that narrows in width in the thickness direction, or, on the other hand, the delivery groove 313 can be protruded to form an injection protrusion 314. Thereby, the drug delivery portion 13 is protruded on the finally completed nucleic acid membrane 10, or, on the other hand, the drug injection hole 14 is formed through the drug delivery portion 13.

[0093] In the membrane acquisition step S7, the nucleic acid membrane 10 is separated from the molding mold 5 after the drying step S4. The nucleic acid membrane 10 of a predetermined thickness can be obtained by the membrane acquisition step S7. Here, the thickness of the formed nucleic acid membrane 10 can be 10 nm to several hundred μm. As an example, the thickness of the formed nucleic acid membrane 10 can be several hundred nm.

[0094] In the oblique deposition step S8, the coating layer 15 is formed on the finally completed nucleic acid membrane 10. The coating layer 15 contains inorganic or organic substances that are not decomposed by the decomposition liquid 50 described later, and can be composed of substances harmless to the human body. As an example, the coating layer 15 can contain substances such as gold, silver, and the like as a main raw material. The shape of the nucleic acid membrane 10 can be stably maintained by the oblique deposition step S8. In particular, by the oblique deposition step S8, the shape of the microneedle 11, the buffer groove 12, and the drug delivery portion 13 protruded on the nucleic acid membrane 10 can be maintained for a long time, and the flat state of the nucleic acid membrane 10 or the state in which the nucleic acid membrane 10 is adhered to the human body can be maintained for a long time.

[0095] As shown in (a) and (b), the oblique deposition step S8 is performed on the nucleic acid membrane 10 finally completed by the drying step S4 or the membrane acquisition step S7 in the first mold 301 or the second mold 302 or the third mold 303 of the molding mold 5. Figure 1 Figure 5 At this time, the nucleic acid membrane 10 finally completed by the drying step S4 or the membrane acquisition step S7 includes the microneedle 11 or the drug delivery portion 13 elongated toward the skin of the human body.

[0096] Thereby, the coating layer 15 is formed in the oblique deposition step S8, and the coating layer 15 at least wraps the microneedle 11 so that the tip portion of the microneedle 11 is exposed, or the coating layer 15 at least wraps the drug delivery portion 13 so that the tip portion of the drug delivery portion 13 is exposed. In particular, in the nucleic acid membrane 10 in which the drug delivery portion 13 is formed, the drug injection hole 14 described later is prevented from being clogged by the coating layer 15.

[0097] Thereby, the coating layer 15 is formed in the oblique deposition step S8, and the coating layer 15 at least wraps the microneedle 11 so that the tip portion of the microneedle 11 is exposed, or the coating layer 15 at least wraps the drug delivery portion 13 so that the tip portion of the drug delivery portion 13 is exposed. In particular, in the nucleic acid membrane 10 in which the drug delivery portion 13 is formed, the drug injection hole 14 described later is prevented from being clogged by the coating layer 15.

[0098] ​In the oblique deposition step S8, the coating layer 15 can be formed to at least cover the microneedle 11 with the tip portion of the microneedle 11 being covered by the first deposition auxiliary member 15a. In addition, in the oblique deposition step S8, the coating layer 15 can be formed to at least cover the drug delivery portion 13 with the tip portion of the drug delivery portion 13 being covered by the first deposition auxiliary member 15a. Further, after the coating layer 15 is formed in the oblique deposition step S8, the first deposition auxiliary member 15a is separated from the nucleic acid membrane 10.

[0099] First, the exposure of the tip portion of the microneedle 11 or the tip portion of the drug delivery portion 13 indicates a case where the coating layer 15 is formed with respect to the nucleic acid membrane 10 completed using the first mold 301 as follows. The coating layer 15 can cover only the microneedle 11 excluding the tip portion of the microneedle 11, can cover the microneedle 11 excluding the tip portion of the microneedle 11 and a part of one side surface of the nucleic acid membrane 10 including the same, or can cover the microneedle 11 excluding the tip portion of the microneedle 11 and the entire one side surface of the nucleic acid membrane 10 including the same.

[0100] Second, the exposure of the tip portion of the microneedle 11 or the tip portion of the drug delivery portion 13 indicates a case where the coating layer 15 is formed with respect to the nucleic acid membrane 10 completed using the second mold 302 as follows. The coating layer 15 can cover only the outer surface of the buffer groove 12, can cover only the outer surface of the buffer groove 12 and the microneedle 11 excluding the tip portion of the microneedle 11, can cover at least the outer surface of the buffer groove 12 and a part of one side surface of the nucleic acid membrane 10 including the same, or can cover at least the outer surface of the buffer groove 12 and the entire one side surface of the nucleic acid membrane 10 including the same.

[0101] Third, the exposure of the tip portion of the microneedle 11 or the tip portion of the drug delivery portion 13 indicates a case where the coating layer 15 is formed with respect to the nucleic acid membrane 10 completed using the third mold 303 as follows. The coating layer 15 can cover only the drug delivery portion 13 excluding the tip portion of the drug delivery portion 13, can cover the drug delivery portion 13 excluding the tip portion of the drug delivery portion 13 and a part of one side surface of the nucleic acid membrane 10 including the same, or can cover the drug delivery portion 13 excluding the tip portion of the drug delivery portion 13 and the entire one side surface of the nucleic acid membrane 10 including the same.

[0102] Thus, the method of manufacturing the nucleic acid membrane according to the first embodiment of the present application can form the coating layer on the microneedle 11, the buffer groove 12, and the drug delivery portion 13 formed with the drug injection hole 14 in the finally completed nucleic acid membrane 10.

[0103] The tip portion of the microneedle 11 or the tip portion of the drug delivery portion 13 can be exposed by inclined deposition, local plating, local coating, sputtering, or the like in the inclined deposition step S8. In the first embodiment of the present application, the tip portion of the microneedle 11 or the tip portion of the drug delivery portion 13 can be exposed by inclined deposition. Thus, the inclined deposition step S8 includes a process of curing the coating layer 15.

[0104] Thus, the coating layer 15 is formed on the finally completed nucleic acid membrane 10 so as to expose the tip portion of the microneedle 11 or the tip portion of the drug delivery portion 13.

[0105] Next, the method of producing the nucleic acid membrane of the second embodiment of the present application will be described. Figure 6 For the purpose of illustrating the flow of the method of producing the nucleic acid membrane of the second embodiment of the present application, Figure 7 For the purpose of illustrating the process state of forming the coating layer on the nucleic acid membrane by forming the coating layer on the molding die in the method of producing the nucleic acid membrane of the second embodiment of the present application, a drawing is shown.

[0106] In the upper portion of the drawing, Figure 7 the upper portion shows the state in which the coating layer 15 is formed on the molding die 5, Figure 7 the middle portion shows the state in which the nucleic acid membrane 10 is layered on the molding die 5 on which the coating layer 15 is formed, Figure 7 and the lower portion shows the state in which the nucleic acid membrane 10 and the coating layer 15 are separated from the molding die 5 in the state in which the coating layer 15 is fixed on the nucleic acid membrane 10.

[0107] With reference to Figure 6 and Figure 7 the method of producing the nucleic acid membrane of the second embodiment of the present application includes the mixing step S1, the stirring step S2, the mixed solution coating step S3, and the drying step S4.

[0108] Further, the method of producing the nucleic acid membrane of the second embodiment of the present application can further include at least one of the surface treatment step S5, the mold preparation step S6, the membrane acquisition step S7, and the inclined deposition step S8.

[0109] In the method of producing the nucleic acid membrane of the second embodiment of the present application, the same reference numerals are given to the same components as those of the method of producing the nucleic acid membrane of the first embodiment of the present application, and the description thereof will be omitted.

[0110] However, in the inclined deposition step S8, the coating layer 15 is fixed on the nucleic acid membrane 10 after the coating layer 15 is formed on the molding die 5.

[0111] As Figure 6 and Figure 7As shown, the inclined deposition step S8 is performed on the first mold 301 or the second mold 302 in the molding mold 5 before the mixed solution coating step S3. In other words, the inclined deposition step S8 is performed on the first mold 301 or the second mold 302 or the third mold 303 in the molding mold 5 between the surface treatment step S5 and the mixed solution coating step S3.

[0112] At this time, the molding mold 5 includes the needle groove 311 in which the recess is formed and the width in the thickness direction is narrowed, through the mold preparation step S6.

[0113] Thus, in the inclined deposition step S8, the coating layer 15 is formed at least at the inlet portion of the needle groove 311 other than the end portion of the needle groove 311 before the mixed solution coating step S3.

[0114] As one example, the coating layer 15 is formed with respect to the first mold 301 as follows other than the end portion of the needle groove 311. The coating layer 15 can be formed only at the inlet portion of the needle groove 311, can be formed at the inlet portion of the needle groove 311 and a part of one side surface of the molding mold 5 including the same, or can be formed at the inlet portion of the needle groove 311 and the entire one side surface of the molding mold 5 including the same.

[0115] As another example, the coating layer 15 is formed with respect to the second mold 302 as follows other than the end portion of the needle groove 311. The coating layer 15 can also be formed at the buffer formation groove 312. The coating layer 15 can be formed only at the buffer formation groove 312, can be formed at the buffer formation groove 312 and the inlet portion of the needle groove 311, can be formed at least at the buffer formation groove 312 and a part of one side surface of the molding mold 5 including the same, or can be formed at least at the buffer formation groove 312 and the entire one side surface of the molding mold 5 including the same.

[0116] As another example, the coating layer 15 is formed with respect to the third mold 302 as follows other than the end portion of the needle groove 311. The coating layer 15 can also be formed at the delivery groove 313. The coating layer 15 can be formed only at the delivery groove 313, can be formed at least at the delivery groove 313 and a part of one side surface of the molding mold 5 including the same, or can be formed at least at the delivery groove 313 and the entire one side surface of the molding mold 5 including the same. At this time, the injection protrusion 314 does not interfere with the formation process of the coating layer 15.

[0117] Although not shown, in the inclined deposition step S8, the coating layer 15 can be formed at the inlet portion of the needle groove 311 or the delivery groove 312 in a state in which the end portion of the needle groove 311, the end portion of the buffer formation groove 312, and the end portion of the delivery groove 313 are closed by a separate deposition auxiliary member (not shown), and then the separate deposition auxiliary member (not shown) is separated.

[0118] The tip portion of the needle groove 311, the tip portion of the buffer forming groove 312, and the tip portion of the delivery groove 313 can be excluded by oblique deposition, local plating, local coating, sputtering, or the like in the oblique deposition step S8. In the second embodiment of the present application, the coating layer 15 can be formed by oblique deposition. The oblique deposition step S8 includes a process of curing the coating layer 15.

[0119] Thus, after the mixed solution coating step S3, the mixed solution is not only filled into the needle groove 311 but also coated on the molding mold 5, and after the drying step S4, the finally completed nucleic acid membrane 10 is formed with the integrated coating layer 15. Thus, the integrated nucleic acid membrane 10 and the coating layer 15 are simultaneously separated from the molding mold 5 in the membrane obtaining step S7.

[0120] Thus, the coating layer 15 is formed on the finally completed nucleic acid membrane 10 so that the tip portion of the microneedle 11 formed by the needle groove 311 is exposed.

[0121] Next, the nucleic acid membrane preparation method of the third embodiment of the present application will be described. Figure 8 A flowchart of the nucleic acid membrane preparation method of the third embodiment of the present application is shown in FIG. 10. Figure 9 A diagram of the process state in which the coating layer is incorporated in the nucleic acid membrane in the nucleic acid membrane preparation method of the third embodiment of the present application is shown in FIG. 11.

[0122] In FIG. 11, Figure 9 the uppermost portion shows a state in which the buffer groove 12 is formed on the nucleic acid membrane 10, Figure 9 the middle upper portion shows a state in which the coating layer 15 is layered on the nucleic acid membrane 10 on which the buffer groove 12 is formed, Figure 9 the middle lower portion shows a state in which the finishing layer 100 is layered in a state in which the coating layer 15 is layered on the nucleic acid membrane 10, and Figure 9 the lowermost portion shows a state in which the molding mold 5 is separated from the nucleic acid membrane 10 in a state in which the coating layer 15 and the finishing layer 100 are fixed on the nucleic acid membrane 10.

[0123] Referring to Figure 8 and Figure 9 the nucleic acid membrane preparation method of the third embodiment of the present application includes a mixing step S1, a stirring step S2, a mixed solution coating step S3, and a drying step S4.

[0124] In addition, the nucleic acid membrane preparation method of the third embodiment of the present application can further include at least one of a surface treatment step S5, a mold preparation step S6, and a membrane obtaining step S7.

[0125] In the nucleic acid membrane preparation method of the third embodiment of the present application, the same reference numerals are given to the same components as those of the nucleic acid membrane preparation method of the first embodiment or the second embodiment of the present application, and the description thereof will be omitted.

[0126] However, the method of manufacturing the nucleic acid membrane of the third embodiment of the present application can further include the oblique deposition step S8, and can further include the finishing coating step S9 and the finishing drying step S10.

[0127] In the third embodiment of the present application, the coating layer 15 is layered on the nucleic acid membrane 10, and the finishing layer 100 is layered thereon, so that the coating layer 15 is housed between the nucleic acid membrane 10 and the finishing layer 100.

[0128] As one example, the microneedle 11 or the drug delivery portion 13 is formed on one side of the finally completed nucleic acid membrane 10. Thereby, the coating layer 15 is formed on the other side of the nucleic acid membrane 10 in the oblique deposition step S8 so that the portion corresponding to the microneedle 11 or the drug delivery portion 13 becomes an opening. Then, the finishing liquid can be coated on the other side of the nucleic acid membrane 10 on which the coating layer 15 is formed by the finishing coating step S9, and the finishing liquid can be dried by the finishing drying step S10 so that the finishing liquid coated on the nucleic acid membrane 10 is changed into the finishing layer 100. Thereby, the nucleic acid membrane 10 in which the coating layer 15 and the finishing layer 100 are formed in one body can be obtained in the membrane obtaining step S7.

[0129] As another example, before the oblique deposition step S8, the one side of the nucleic acid membrane 10 includes the microneedle 11 elongated toward the skin of the human body, and the other side of the nucleic acid membrane 10 is recessed to form the buffer groove 12 corresponding to the microneedle 11, by the mixed liquid coating step S3 and the drying step S4.

[0130] At this time, as described above, the buffer groove 12 can be formed using the second mold 302 in the molding mold 5.

[0131] Further, as shown in the uppermost part of FIG. 1, Figure 9 As shown in the uppermost part of FIG. 1, the buffer groove 12 can be formed by inserting the groove forming member (not shown) having a form corresponding to the form of the needle groove 311 or the buffer forming groove 312 or the delivery groove 313 into the needle groove 311 or the buffer forming groove 312 or the delivery groove 313 after the mixed liquid coating step S3 or during the drying step S4, and separating the groove forming member 10a from the nucleic acid membrane 10 after the drying step S4. At this time, depending on the use state of the groove forming member 10a, the buffer groove 12 and the microneedle 11 can be formed on the nucleic acid membrane 10, or the drug delivery portion 13 in which the drug injection hole 14 is formed can be formed.

[0132] Thereby, as shown in FIG. 2, Figure 8 and Figure 9 As shown in FIG. 2, the coating layer 15 is formed at least at the inlet portion of the buffer groove 12 except for the end portion of the buffer groove 12 in the oblique deposition step S8 after the drying step S4.

[0133] In this case, the expression "except for the end portion of the buffer groove 12" means that the end portion of the buffer groove 12 is opened, and indicates a case where the coating layer 15 is formed with respect to the nucleic acid membrane 10 as follows. The coating layer 15 can be formed only at the inlet portion of the buffer groove 12, or can be formed at the inlet portion of the buffer groove 12 and a portion of the other side surface of the nucleic acid membrane 10 including the same, or can be formed at the inlet portion of the buffer groove 12 and the entire other side surface of the nucleic acid membrane 10 including the same.

[0134] Although not illustrated, the expression "except for the end portion of the buffer groove 12" indicates a case where the coating layer 15 is formed at least on the inner wall of the drug injection hole 14 to maintain the open state of the drug injection hole 14.

[0135] Although not illustrated, in the inclined deposition step S8, the coating layer 15 can be formed at the inlet portion of the buffer groove 12 in a state where the end portion of the buffer groove 12 is closed by a separate deposition auxiliary member (not illustrated), and then the separate deposition auxiliary member (not illustrated) can be separated.

[0136] In the inclined deposition step S8, the end portion of the buffer groove 12 can be excluded by various forms such as inclined deposition, partial plating, partial coating, sputtering, etc. In the third embodiment of the present application, the coating layer 15 can be formed by inclined deposition. The inclined deposition step S8 includes a process of curing the coating layer 15.

[0137] Further, in the finishing coating step S9, after the inclined deposition step S8, a finishing liquid is coated on the nucleic acid membrane 10 so that the finishing liquid not only fills the buffer groove 12 but also wraps the coating layer 15. In this case, the finishing liquid is used to form the finishing layer 100, and the finishing liquid can include the mixed liquid described above in order to form the nucleic acid membrane, or the finishing liquid can include a mixed liquid containing vitamins, collagen, etc. in order to form a separate water-soluble functional membrane. At this time, the finishing liquid can include a drug for absorption into the human body.

[0138] In the finishing drying step S10, the finishing liquid coated on the nucleic acid membrane 10 is dried so that the finishing liquid coated on the molding die 5 is changed into the finishing layer 100. Thus, the finishing layer 100 can form the nucleic acid membrane described above, or can form a separate water-soluble functional membrane.

[0139] Thus, after the membrane acquisition step S7, the nucleic acid membrane 10 finally completed can form a state in which the coating layer 15 and the finishing layer 100 are integrated. At this time, the structure in which the coating layer 15 is contained between the finishing layer 100 and the nucleic acid membrane 10 is formed.

[0140] Although not illustrated, in the method of forming the buffer groove 12 on the nucleic acid membrane 10 according to the third embodiment of the present application, the buffer groove 12 or the drug delivery portion 13 in which the drug injection hole 14 is formed can also be implemented on the finishing layer 100.

[0141] As an example, the buffer groove 12 or the drug injection hole 14 of the finishing layer 100 can be formed by inserting a groove forming member (not shown) of different size from the groove forming member inserted into the nucleic acid film 10 in the above-described preparation method of the nucleic acid film, into the finishing layer 100 after the finishing coating step S9, or during the finishing drying step S10, and separating the groove forming member from the finishing layer 100 after the finishing drying step S10.

[0142] Next, the drug injection device using the nucleic acid film of the first embodiment of the present application will be described. Figure 10 To illustrate the cross-sectional view of the drug injection device using the nucleic acid film of the first embodiment of the present application. Referring to Figures 1 to 9 and Figure 10 The drug injection device using the nucleic acid film of the first embodiment of the present application applies the nucleic acid film 10 prepared according to the above-described preparation method of the nucleic acid film.

[0143] The drug injection device using the nucleic acid film of the first embodiment of the present application includes: a nucleic acid film 10, a finishing film 30, and a drug 40.

[0144] The nucleic acid film 10 is prepared according to the above-described preparation method of the nucleic acid film, and is brought into contact with the skin of a human body. At this time, the microneedle 11 can be formed protruding on the nucleic acid film 10 through the needle groove 311 formed on the molding die 5. The microneedle 11 can be formed extending from the surface of the nucleic acid film 10 toward the skin of the human body.

[0145] The cross-sectional area of the microneedle 11 gradually decreases from the surface of the nucleic acid film 10, thereby showing a conical shape that is wide at the top and narrow at the bottom. In the microneedle 11, the maximum diameter (the diameter of a virtual circle inscribed in the cross-sectional area of the microneedle 11) of the surface side of the nucleic acid film 10 can be 200 to 400 micrometers, the diameter of the tip portion of the microneedle 11 can be 20 to 30 micrometers, and the protruding length of the microneedle 11 can be 200 to 300 micrometers. If the numerical values of the microneedle 11 deviate from the above-described range, the shape of the microneedle 11 can collapse or bend on the nucleic acid film 10, etc. However, the first embodiment of the present application limits the numerical values of the microneedle 11, thereby stably maintaining the protruding shape on the nucleic acid film 10, facilitating skin penetration of the drug 40, preventing the microneedle 11 from bending or breaking, and preventing the microneedle 11 from breaking when the nucleic acid film 10 is separated from the molding die 5.

[0146] Although not shown, a coating layer 15 is formed on the nucleic acid film 10 so that the tip portion of the microneedle 11 is exposed. The coating layer 15 formed on the nucleic acid film 10 can be formed by the above-described preparation method of the nucleic acid film.

[0147] In addition, in addition to the coating layer 15, a finishing layer 100 may be formed on the nucleic acid film 11. The coating layer 15 and the finishing layer 100 formed on the nucleic acid film 10 may be achieved by the above-mentioned method for preparing the nucleic acid film.

[0148] By forming the coating layer 15 , the strength of the microneedles 11 can be increased, and bending or breaking of the microneedles 11 can be prevented.

[0149] The finishing film 30 is stacked and supported on the nucleic acid film 10. The finishing film 30 can be in various forms to prevent the drug 40 from deteriorating, and is not particularly limited.

[0150] The drug 40 is filled between the nucleic acid film 10 and the finishing film 30. The drug 40 does not decompose the nucleic acid film 10. The drug 40 can be composed of any substance selected from pharmaceuticals used for treatment or health support, including hormone regulation, anesthesia, skin aging prevention, wrinkle removal, tattoo removal, tattoo formation, and skin adsorption. As an example, the drug 40 can include hyaluronic acid for skin aging prevention or wrinkle removal.

[0151] Therefore, when the nucleic acid film 10 is attached to the human skin, the nucleic acid film 10 is decomposed due to the moisture remaining on the surface of the nucleic acid film 10 or the moisture remaining on the human skin or the distilled water or deionized water coated on at least one of the nucleic acid film 10 and the human skin, so that the drug 40 can penetrate into the human skin.

[0152] The drug injection device using the nucleic acid membrane of the first embodiment of the present invention may further include a boundary membrane 20. The boundary membrane 20 is layered and supported between the nucleic acid membrane 10 and the finishing membrane 30. Thus, the drug 40 is filled between the nucleic acid membrane 10 and the boundary membrane 20. Furthermore, a decomposition solution 50 is filled between the boundary membrane 20 and the finishing membrane 30. The decomposition solution 50 may be composed of distilled water or deionized water. In this case, a piercing needle 31 is formed protruding from the finishing membrane 30 to pierce the boundary membrane 20.

[0153] Therefore, when the drug injection device is attached to the human skin and pressurized without separately coating distilled water or deionized water on the nucleic acid membrane 10, the piercing needle 31 pierces the boundary membrane 20, causing the decomposition liquid 50 to move to the side of the drug 40, thereby decomposing the nucleic acid membrane 10 by the decomposition liquid 50, so that the drug 40 can penetrate into the human skin.

[0154] Next, a drug injection device using a nucleic acid membrane according to a second embodiment of the present invention will be described. Figure 11 This is a cross-sectional view illustrating a drug injection device using a nucleic acid membrane according to a second embodiment of the present invention. Figures 1 to 9 and Figure 11The drug injection device using the nucleic acid membrane of the second embodiment of the present application can include the nucleic acid membrane 10, the boundary membrane 20, the finishing membrane 30, the drug 40, and the decomposition liquid 50.

[0155] The drug injection device using the nucleic acid membrane of the second embodiment of the present application can include the nucleic acid membrane 10, the boundary membrane 20, the finishing membrane 30, the drug 40, and the decomposition liquid 50.

[0156] The nucleic acid membrane 10 is prepared according to the preparation method of the nucleic acid membrane described above, and is contacted with the skin of the human body. At this time, the buffer groove 12 can be concavely formed on the nucleic acid membrane 10 by the buffer forming groove 312 formed on the molding die 5. The buffer groove 12 forms a space for accommodating the drug 40. In addition, the microneedle 11 can be protrusively formed on the buffer groove 12 by the needle groove 311. Thus, the buffer groove 12 can be bulged and protrusively formed toward the skin of the human body, and the microneedle 11 can be elongately formed from the buffer groove 12 toward the skin of the human body.

[0157] The boundary membrane 20 is laminated and supported on the nucleic acid membrane 10. The boundary membrane 20 can separate the drug 40 and the decomposition liquid 50 in various forms, and can be perforated by the perforating needle 31 protrusively formed on the finishing membrane 30, and is not limited.

[0158] Although not shown, the coating layer 15 is formed on the nucleic acid membrane 10 so that the end portion of the microneedle 11 is exposed. The coating layer 15 formed on the nucleic acid membrane 10 can be implemented by the preparation method of the nucleic acid membrane described above.

[0159] In addition, the finishing layer 100 can be formed on the nucleic acid membrane 11 in addition to the coating layer 15. The coating layer 15 and the finishing layer 100 formed on the nucleic acid membrane 10 can be implemented by the preparation method of the nucleic acid membrane described above.

[0160] By forming the coating layer 15, the strength of the microneedle 11 can be strengthened, and the bending or breaking of the microneedle 11 can be prevented.

[0161] The finishing membrane 30 is laminated and supported on the boundary membrane 20. The finishing membrane 30 can prevent the drug 40 from deteriorating in various forms, and is not particularly limited. At this time, the perforating needle 31 for perforating the boundary membrane 20 is protrusively formed on the finishing membrane 30.

[0162] The drug 40 is filled between the nucleic acid membrane 10 and the boundary membrane 20. The drug 40 does not decompose the nucleic acid membrane 10 described above. The drug 40 can be composed of any one substance selected from among medicines for treatment or for assisting health, including hormone regulation, anesthesia, prevention of skin aging, wrinkle removal, tattoo removal, tattoo formation, and skin adsorption. As one example, the drug 40 can include hyaluronic acid for preventing skin aging or removing wrinkles.

[0163] The decomposition solution 50 is filled between the boundary film 20 and the finishing film 30. The decomposition solution 50 can be composed of distilled water or deionized water.

[0164] Thus, without separately applying distilled water or deionized water to the nucleic acid film 10, when the drug injection device is attached to the skin of a human body and is pressed, the perforating needle 31 perforates the boundary film 20, the decomposition solution 50 moves to the drug 40 side, and thus the nucleic acid film 10 is decomposed by the decomposition solution 50, so that the drug 40 can permeate into the skin of the human body.

[0165] Next, a drug injection device using the nucleic acid film of the third embodiment of the present application will be described. Figure 12 To illustrate a cross-sectional view of the drug injection device using the nucleic acid film of the third embodiment of the present application. Referring to Figures 1 to 9 and Figure 12 , the drug injection device using the nucleic acid film of the third embodiment of the present application applies the nucleic acid film 10 prepared according to the above-described preparation method of the nucleic acid film.

[0166] The drug injection device using the nucleic acid film of the third embodiment of the present application includes a nucleic acid film 10, a boundary film 20, a finishing film 30, a drug 40, and a decomposition solution 50.

[0167] The nucleic acid film 10 is prepared according to the above-described preparation method of the nucleic acid film and is brought into contact with the skin of a human body. At this time, the drug delivery portion 13 can be protrusively formed on the nucleic acid film 10 through the delivery groove 313 formed on the molding die 5. In addition, the drug injection hole 14 can be formed through the drug delivery portion 13 through the injection protrusion 314. Thus, the drug delivery portion 13 is elongated from the nucleic acid film 10 toward the skin of a human body, and the drug injection hole 14 does not leak the drug 40 due to the surface tension of the drug 40.

[0168] Although not illustrated, a coating layer 15 is formed on the nucleic acid film 10 so that the tip portion of the microneedle 11 is exposed. The coating layer 15 formed on the nucleic acid film 10 can be implemented through the above-described preparation method of the nucleic acid film.

[0169] In addition, the finishing layer 100 can be formed on the nucleic acid film 11 in addition to the coating layer 15. The coating layer 15 and the finishing layer 100 formed on the nucleic acid film 10 can be implemented through the above-described preparation method of the nucleic acid film.

[0170] By forming the coating layer 15, the strength of the microneedle 11 can be strengthened, and the bending or breakage of the microneedle 11 can be prevented.

[0171] The boundary film 20 is layered and supported on the nucleic acid film 10. The boundary film 20 can separate the drug 40 and the decomposition liquid 50 in various forms, and can be perforated by the perforating needle 31 protruding from the finishing film 30, and is not limited.

[0172] The finishing film 30 is layered and supported on the boundary film 20. The finishing film 30 can prevent the drug 40 from deteriorating in various forms, and is not particularly limited. At this time, the finishing film 30 has the perforating needle 31 protruding to perforate the boundary film 20.

[0173] The drug 40 is filled between the nucleic acid film 10 and the boundary film 20. The drug 40 does not decompose the nucleic acid film 10. The drug 40 can be composed of any one substance selected from among pharmaceuticals for treatment or for assisting health, including hormone regulation, anesthesia, prevention of skin aging, wrinkle removal, tattoo removal, tattoo formation, skin absorption, and the like. As an example, the drug 40 can include hyaluronic acid for preventing skin aging or removing wrinkles.

[0174] The decomposition liquid 50 is filled between the boundary film 20 and the finishing film 30. The decomposition liquid 50 can be composed of distilled water or deionized water.

[0175] Thus, without separately applying distilled water or deionized water to the nucleic acid film 10, when the drug injection device is attached to the skin of a human body and is pressurized, the perforating needle 31 perforates the boundary film 20, the decomposition liquid 50 moves to the side of the drug 40, and thus the nucleic acid film 10 is decomposed by the decomposition liquid 50, so that the drug 40 can penetrate into the skin of the human body.

[0176] The drug injection device using the nucleic acid film of the third embodiment of the present application can further include a protective film 60, and can further include a separation layer 70.

[0177] The protective film 60 is combined with the nucleic acid film 10 in a detachable state to open and close the drug injection hole 14. In addition, the separation layer 70 is fixed to the protective film 60 in a detachable state on the nucleic acid film 10. The separation layer 70 must not be mixed with the drug 40.

[0178] Thus, the protective film 60 or the separation layer 70 can further prevent the drug 40 from leaking from the drug injection hole 14 when the drug injection device is transported or stored, and can prevent foreign matter from flowing into the drug injection hole 14.

[0179] Next, a drug injection device using a nucleic acid film of a fourth embodiment of the present application will be described. Figure 13 To illustrate a cross-sectional view of a drug injection device using a nucleic acid film of a fourth embodiment of the present application. Referring to Figures 1 to 9 and Figure 13The nucleic acid membrane 10 is prepared by mixing the nucleic acid 1b and the drug 40 in the aqueous solution 1b in the above-described preparation method.

[0180] The drug injection device using the nucleic acid membrane of the fourth embodiment of the present application is composed of the nucleic acid membrane 10. The nucleic acid membrane 10 is prepared by mixing the nucleic acid 1b and the drug 40 in the aqueous solution 1b in the above-described preparation method. The micro-needles 11 of the first embodiment of the present application can be formed on the nucleic acid membrane 10.

[0181] Although not illustrated, a coating layer 15 is formed on the nucleic acid membrane 10 so that the tip portions of the micro-needles 11 are exposed. The coating layer 15 formed on the nucleic acid membrane 10 can be achieved by the above-described preparation method of the nucleic acid membrane.

[0182] In addition, a finishing layer 100 can be formed on the nucleic acid membrane 11 in addition to the coating layer 15. The coating layer 15 and the finishing layer 100 formed on the nucleic acid membrane 10 can be achieved by the above-described preparation method of the nucleic acid membrane.

[0183] By forming the coating layer 15, the strength of the micro-needles 11 can be enhanced, and the bending or breaking of the micro-needles 11 can be prevented.

[0184] The drug injection device using the nucleic acid membrane of the fourth embodiment of the present application can further include the boundary membrane 20, the finishing membrane 30, and the decomposition solution 50.

[0185] The boundary membrane 20, the finishing membrane 30, and the decomposition solution 50 of the fourth embodiment of the present application are the same as those of the drug injection device of any one of the first to third embodiments of the present application, and thus a description thereof will be omitted.

[0186] According to the above-described preparation method of the nucleic acid membrane and the drug injection device using the nucleic acid membrane, by applying the nucleic acid membrane 10 in a transdermal delivery technique that relies on the diffusion of a drug through the skin of a human body, skin problems can be prevented, and the skin permeability of the drug 40 can be improved. In addition, the micro-needles 11, the buffer grooves 12, the drug delivery portions 13 in which the drug injection holes 14 are formed, can be easily formed on the nucleic acid membrane 10, and a certain thickness of the nucleic acid membrane 10 can be formed.

[0187] In addition, the mixing of foreign substances into the nucleic acid membrane 10 can be prevented, and the degree of decomposition of the nucleic acid membrane 10 can be improved. In addition, the decomposition solution 50 can be stably supplied to the nucleic acid membrane 10, and the supply of the drug 40 can be stabilized. In addition, a pattern according to the input form of the drug 40 can be formed, and the input amount of the drug 40 can be adjusted according to the pattern.

[0188] Further, leakage of the drug 40 from the drug injection hole 14 can be prevented, foreign matter can be prevented from being mixed in the drug 40, and the nucleic acid film 10 can be protected.

[0189] As described above, the preferred embodiments of the present application have been described with reference to the accompanying drawings, but a person skilled in the art can make various modifications or changes to the present application within the scope of the idea and the field of the present application recited in the claims.

[0190] Explanation of the Markings

[0191] S1: Mixing Step S2: Stirring Step

[0192] S3: Mixed Liquid Coating Step S4: Drying Step

[0193] S5: Surface Treatment Step S6: Mold Preparation Step

[0194] S7: Film Acquisition Step S8: Inclined Deposition Step

[0195] S9: Finishing Coating Step S10: Finishing Drying Step

[0196] 1: Mixing Container 1a: Aqueous Solution

[0197] 1b: Nucleic Acid 2: Stirring Unit

[0198] 3: Magnet 4: Sealing Material

[0199] 5: Molding Mold 301: First Mold

[0200] 302: Second Mold 303: Third Mold

[0201] 311: Needle Groove 312: Buffer Forming Groove

[0202] 313: Delivery Groove 314: Injection Protrusion

[0203] 6: Surface Treatment Unit 7: Drying Unit

[0204] 8: Pipetting Unit 10: Nucleic Acid Film

[0205] 100: Finishing Layer 10a: Groove Forming Member

[0206] 11: Microneedle 12: Buffer Groove

[0207] 13: Drug Delivery Port 14: Drug Injection Hole

[0208] 15: Coating Layer 15a: First Deposition Auxiliary Member

[0209] 20: Boundary Film 30: Finishing Film

[0210] 31: piercing needle 40: medicine

[0211] 50: decomposition liquid 60: protective film

[0212] 70: separation layer

Claims

1. A method for preparing a nucleic acid membrane, comprising the following steps: a mixing step, wherein 0.5 to 5 parts by weight of nucleic acid in powder form is added to 100 parts by weight of distilled water or deionized water to form a mixed solution; a stirring step, wherein the mixed liquid after the mixing step is stirred; a mixed solution coating step, wherein the mixed solution is coated on a forming mold corresponding to the shape of the nucleic acid membrane to be completed; and a drying step, wherein the mixed solution coated on the forming mold is dried to convert the mixed solution coated on the forming mold into the nucleic acid film; Furthermore, the method further comprises a film obtaining step, wherein after the drying step, the nucleic acid film is separated from the forming mold. wherein the nucleic acid membrane in the membrane obtaining step is composed only of nucleic acids, The forming mold is formed with a groove portion recessed in the thickness direction; A protrusion is formed on the nucleic acid film after the drying step. The protrusion corresponds to the groove and protrudes from one side surface of the nucleic acid film toward the skin of the human body.

2. The method for preparing a nucleic acid membrane according to claim 1, wherein: The preparation method further includes an oblique deposition step in which, after the drying step, a coating is formed on one side of the nucleic acid film so that the terminal end of the protrusion is exposed.

3. The method for preparing a nucleic acid membrane according to claim 1, wherein: The manufacturing method further includes an oblique deposition step of forming a coating layer on the molding die except for a terminal end portion of the groove portion before the mixed liquid coating step.

4. The method for preparing a nucleic acid membrane according to claim 1, wherein: The preparation method further includes an oblique deposition step, wherein after the drying step, a coating is formed on the other side of the nucleic acid film so that a portion corresponding to the protrusion becomes an opening.

5. The method for preparing a nucleic acid membrane according to claim 4, wherein: The preparation method further comprises the following steps: a finishing coating step, wherein after the oblique deposition step, a finishing liquid is applied to wrap the coating layer; and The finishing drying step comprises drying the finishing liquid to convert the finishing liquid into a finishing layer.

6. The method for preparing a nucleic acid membrane according to claim 1, wherein: The preparation method further comprises at least one of the following steps: a mold preparation step, wherein, before the mixed solution coating step, the molding mold is processed in a manner corresponding to the morphology of the nucleic acid membrane to be completed; and A surface treatment step, wherein the surface of the molding die is treated to be hydrophobic before the mixed solution coating step.

7. The method for preparing a nucleic acid membrane according to any one of claims 1 to 6, characterized in that: The nucleic acid is extracted from at least one of aquatic product processing by-products formed by processing aquatic products and agricultural product processing by-products formed by processing plants.

8. A drug injection device using a nucleic acid membrane, comprising: A nucleic acid membrane prepared according to the preparation method of claim 1, for contact with human skin; an arrangement membrane layered on the nucleic acid membrane; as well as The drug is filled between the nucleic acid film and the finishing film.

9. The drug injection device using nucleic acid membrane according to claim 8, characterized in that: The device further comprises: a boundary film layered between the nucleic acid film and the finishing film; and a decomposition liquid filled between the boundary film and the finishing film and consisting of distilled water or deionized water; wherein a perforating needle is formed on the finishing film, and the perforating needle protrudes toward the boundary film to perforate the boundary film; The drug is filled between the nucleic acid film and the boundary film.

10. The drug injection device using nucleic acid membrane according to claim 8, characterized in that: On one side of the nucleic acid membrane, microneedles protrude toward the human skin.

11. The drug injection device using nucleic acid membrane according to claim 10, characterized in that: The other side of the nucleic acid membrane is recessed to form a buffer groove corresponding to the microneedle.

12. The drug injection device using nucleic acid membrane according to claim 10, characterized in that: The device further includes a coating on one side of the nucleic acid membrane, exposing the distal end of the microneedle.

13. The drug injection device using nucleic acid membrane according to claim 10, characterized in that: The device further comprises a coating, wherein the coating is located on the other side of the nucleic acid membrane, and the portion corresponding to the microneedle is an opening.

14. The drug injection device using a nucleic acid membrane according to claim 8, characterized in that: On one side of the nucleic acid membrane, the drug delivery portion protrudes toward the human skin. A drug injection hole is formed through the drug delivery portion to discharge the drug.

15. The drug injection device using nucleic acid membrane according to claim 14, characterized in that: The device further includes a coating layer on one side of the nucleic acid membrane, exposing a terminal end of the drug delivery portion.

16. The drug injection device using nucleic acid membrane according to claim 14, characterized in that: The device further comprises a coating layer, wherein the coating layer is located on the other side of the nucleic acid membrane, and the portion corresponding to the drug injection hole is an opening.

17. The drug injection device using nucleic acid membrane according to claim 14, characterized in that: The device further includes a protective film, which is on one side of the nucleic acid membrane and is detachable on the one side of the nucleic acid membrane to open and close the drug injection hole.

Images